News | December 17, 2023
Briefs: Torrent Pharmaceuticals and Laurus Synthesis
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Laurus Synthesis receives Form 483 with 5 observations from USFDA
The drug will be manufactured at JB Pharma's formulation manufacturing facility in Panoli, Gujarat
Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023
Man Industries (India) Limited has received a new export order of approximately Rs. 1,300 crores.
The company has reported total income of Rs. 2481 crores during the period ended December 31, 2022
The scheme is subject to statutory and regulatory approvals as may be necessary.
Empagliflozin is a novel sodium glucose co-transporter-2 (SGLT-2) inhibitor, which is useful for improving glycaemic control in adults with type-2 diabetes mellitus.
The consideration includes Rs. 115 crore (on the date of signing) of cash and cash equivalents in the acquired business indicating an Enterprise Value of Rs. 1,885 crore
Torrent Pharmaceuticals has reported total income of Rs. 2377 crores during the period ended June 30, 2022.
The integration and transition of the brands are expected to be completed by June 2022.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)